Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

NCT ID: NCT00661141

Last Updated: 2024-12-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2008-06-30

Brief Summary

This trial will evaluate if fomepizole (4-methylpyrazole) can treat symptoms associated with alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) deficiency, an inherited metabolic disorder. These symptoms include flushing, nausea, headache, shortness of breath and dizziness, resulting from exposure to acetaldehyde, the primary metabolite of ethanol. Long-term, serious health risks have been associated with repeated exposure to acetaldehyde, a carcinogen, among ALDH2-deficient individuals.

Detailed Description

Approximately 32 subjects will be enrolled in ascending dosing cohorts of 8 subjects each. Each subject will receive an oral dose of study drug (fomepizole or placebo) with concomitant ethanol with group assignment in a randomized 1:1:1:1 ratio (2 subjects each group) on Study Day 1. Each subject is their own intra-subject control with the alternative study drug (fomepizole or placebo) administered on the next day (Study Day 2). Four subjects in each cohort will receive study drug (fomepizole or placebo) administered 30 minutes prior to ethanol, 4 with study drug (fomepizole or placebo) administered 30 minutes after ethanol. The study will assess safety and tolerability of fomepizole and the PK/PD of 4-MP, ethanol and acetaldehyde in the subject population.

Study with completed results acquired from Horizon in 2024.

Conditions

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

Keywords

acetaldehyde; ethanol; ALDH2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Cohort 1: Antizol 1.0 mg/kg

Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.

Group Type: EXPERIMENTAL

Antizol

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Ethanol

Intervention Type: OTHER

oral dose of ethanol (0.5 g/kg)

Cohort 2: Antizol 3.0 mg/kg

Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.

Group Type: EXPERIMENTAL

Antizol

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Ethanol

Intervention Type: OTHER

oral dose of ethanol (0.5 g/kg)

Cohort 3: Antizol 5.0 mg/kg

Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.

Group Type: EXPERIMENTAL

Antizol

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Ethanol

Intervention Type: OTHER

oral dose of ethanol (0.5 g/kg)

Cohort 4: Antizol 1.0 mg/kg

Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.

Group Type: EXPERIMENTAL

Antizol

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Ethanol

Intervention Type: OTHER

oral dose of ethanol (0.5 g/kg)

Interventions

Antizol

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Ethanol

oral dose of ethanol (0.5 g/kg)

Intervention Type: OTHER

Other Intervention Names

fomepizole; 4-methylpyrazole; 4-MP

Eligibility Criteria

Inclusion Criteria

• Signed informed consent
• Age 21 to 50 years
• Subject of Japanese descent
• History of flushing, with or without palpitations, or nausea (Alcohol Sensitivity Screening Test ≥ 3.1) following occasional or inadvertent ethanol consumption either currently or in the past
• Subjects must be healthy volunteers with no other clinically relevant abnormalities as determined by medical history, blood chemistry, complete blood count (CBC), urinalysis,and 12-lead electrocardiogram (ECG)
• Positive skin ethanol patch test (100 μL of 70% ethanol on a lint pad applied to skin for 7 minutes results in an area of erythema)
• For Cohort 4, enrolled subjects were either homozygous or heterozygous for the ALDH2*2 genotype as assessed by genotyping at Screening

Exclusion Criteria

• Vaccination within 2 weeks of Day 1
• Current respiratory disease or a past history of chronic respiratory disease, or current smoker within last six months
• Any one of the following Screening ECG findings:

• QTc (Bazett) interval duration greater than 450 msec (male) or 470 msec (female), or
• QRS interval greater than 120 msec, or
• PR interval greater than 220 msec
• History or evidence of drug or alcohol abuse or regular consumption of more than 8 units of alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit) or those who may have difficulty abstaining from non study alcohol during the 36 hours prior to dose administration and until completion of blood sampling on Day 7
• Subjects who have donated blood totalling more than 550 mL within the 3 months prior to Day 1
• Use of any prescription medication other than oral contraceptives during the 14 days prior to Day 1, unless approved by both the Principal Investigator (PI) and the Sponsor
• Inability to abstain from smoking any tobacco product from within prior to 2 hours of blood sampling to after 2 hours of blood sampling during the study period.
• Use of any over-the-counter product, herbal product, diet aid, hormone supplement, etc., within 14 days prior to Day 1 unless approved by both the PI and the Sponsor
• Chronic use of pain medications
• Administration of an investigational agent within the last 30 days (or within a period of less than 5 times the agent's half-life, whichever is longer) prior to Day 1
• Major surgery within 60 days prior to Day 1, or any planned surgery or medical procedure during the study period (through Day 7)
• Positive alcohol breath-test or Positive drug screen (e.g., opiates, barbiturates, cannabinoids, benzodiazepines, cocaine, amphetamines) during screening or at Day 0 Check-In
• Known hypersensitivity reaction to Antizol® or other pyrazoles, tomato juice
• Abnormal laboratory results, including:

• WBC ≤3.5 × 109/L or neutrophil count ≤2.0 × 10^9/L
• Hemoglobin <12.0 or >16.0 gm/dL
• Creatinine ≥2 mg/dL
• Total bilirubin ≥2 mg/dL
• Alanine aminotransferase and/or aspartate aminotransferase ≥2 times the upper limit of normal
• PaO2 ≤95% on room air by pulse oximetry
• Urine dipstick positive for protein, blood, ketones, glucose or leukocyte esterase
• Any other clinically significant abnormal result for hematology, clinical chemistry, or urinalysis at screening or check-In
• Positive serum pregnancy test for females of childbearing potential
• Subject and/or partner unable or unwilling to use an effective form of barrier contraceptives during the course of the study and for 7 days after study drug administration.
• Cancer (excluding adequately treated basal cell carcinoma) within the last 5 years
• Significant past medical history of hepatic, renal, cardiovascular (including family history of prolonged QT syndrome), pulmonary, gastrointestinal, hematological, locomotor, immunologic, ophthalmologic, metabolic endocrine or other diseases; or any condition that in the opinion of the Investigator would complicate or compromise the study, or the well-being of the subject
• Any other reason, which in the opinion of the Principal Investigator, would prevent the subject from completing or following the study schedule

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Covance Honolulu CRU

Honolulu, Hawaii, United States

Countries

United States

References

Inoue K, Fukunaga M, Kiriyama T, Komura S. Accumulation of acetaldehyde in alcohol-sensitive Japanese: relation to ethanol and acetaldehyde oxidizing capacity. Alcohol Clin Exp Res. 1984 May-Jun;8(3):319-22. doi: 10.1111/j.1530-0277.1984.tb05519.x.

Reference Type: BACKGROUND

PMID: 6377951 (View on PubMed)

Inoue K, Kera Y, Kiriyama T, Komura S. Suppression of acetaldehyde accumulation by 4-methylpyrazole in alcohol-hypersensitive Japanese. Jpn J Pharmacol. 1985 May;38(1):43-8. doi: 10.1254/jjp.38.43.

Reference Type: BACKGROUND

PMID: 4021229 (View on PubMed)

Tardif R, Liu L, Raizenne M. Exhaled ethanol and acetaldehyde in human subjects exposed to low levels of ethanol. Inhal Toxicol. 2004 Apr;16(4):203-7. doi: 10.1080/08958370490277272.

Reference Type: BACKGROUND

PMID: 15204767 (View on PubMed)

Yokoyama T, Yokoyama A, Kato H, Tsujinaka T, Muto M, Omori T, Haneda T, Kumagai Y, Igaki H, Yokoyama M, Watanabe H, Yoshimizu H. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1227-33.

Reference Type: BACKGROUND

PMID: 14652286 (View on PubMed)

Other Identifiers

BP1-01-01

Identifier Type: -

Identifier Source: org_study_id